Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022

The 24th annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Richmond, British Columbia, on 28–29 October 2022. The WCGCCC is an interactive multidisciplinary conference attended by healthcare professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals such as dieticians, nurses and a genetic counsellor participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancer.

[1]  J. G. van den Berg,et al.  LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study , 2022, Annals of Oncology.

[2]  B. Vogelstein,et al.  318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC) , 2022, Annals of Oncology.

[3]  P. Kasi,et al.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Gonen,et al.  PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.

[5]  J. Ptak,et al.  Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.

[6]  E. Stoffel,et al.  Risk assessment and genetic counseling for Lynch syndrome – Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer , 2022, Journal of genetic counseling.

[7]  H. Hampel,et al.  Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for all GI Cancers? , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Cataldo,et al.  Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Gibbs,et al.  Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. , 2022, The Lancet. Oncology.

[10]  Chen Hu,et al.  Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Valentini,et al.  Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in ypT0-1 Rectal Cancer After Preoperative Radiochemotherapy: Postoperative Morbidity, Functional Results, and Long-term Oncologic Outcome , 2022, Diseases of the colon and rectum.

[12]  C. Andersen,et al.  Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences , 2021, Clinical Cancer Research.

[13]  H. Liu,et al.  Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. , 2021, The lancet. Gastroenterology & hepatology.

[14]  M. Sawyer,et al.  Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Laurent-Puig,et al.  Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial , 2021, Clinical Cancer Research.

[16]  Jeffrey W. Clark,et al.  Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer , 2021, Clinical Cancer Research.

[17]  C. V. van Asperen,et al.  Universal immunohistochemistry for Lynch Syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  T. Conroy,et al.  Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[19]  A. Feber,et al.  Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). , 2021 .

[20]  C. Andersen,et al.  Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. , 2021 .

[21]  A. Darzi,et al.  Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study , 2020, The lancet. Gastroenterology & hepatology.

[22]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[23]  D. Steensma,et al.  What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. , 2020, Blood.

[24]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  O. W. Lindwasser,et al.  ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper , 2020, Nature Reviews Clinical Oncology.

[26]  A. Broeks,et al.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.

[27]  J. Church,et al.  Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis , 2020, Familial Cancer.

[28]  N. Schultz,et al.  Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy , 2020, Clinical Cancer Research.

[29]  E. Dekker,et al.  Update on the World Health Organization Criteria for Diagnosis of Serrated Polyposis Syndrome. , 2020, Gastroenterology.

[30]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. T. Phang,et al.  Rectal cancer DFP dedicated issue: abdominal radiology , 2019, Abdominal Radiology.

[32]  J. Ptak,et al.  Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. , 2019, JAMA oncology.

[33]  J. Ptak,et al.  Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. , 2019, JAMA oncology.

[34]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[35]  R. Yantiss,et al.  Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline , 2019, Journal of global oncology.

[36]  B. Chabner,et al.  Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.

[37]  A. Saklani,et al.  Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. , 2018, Journal of gastrointestinal oncology.

[38]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Biagi,et al.  The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement. , 2017, Current oncology.

[41]  S. Gruber,et al.  Germline Genetic Features of Young Individuals With Colorectal Cancer. , 2017, Gastroenterology.

[42]  M. Hall,et al.  Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults , 2017, JAMA oncology.

[43]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[44]  M. Bertagnolli,et al.  Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). , 2017 .

[45]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[46]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[47]  H. Johansson,et al.  Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. , 2017, The Lancet. Oncology.

[48]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[49]  J. Taïeb,et al.  Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. , 2016, Journal of the National Cancer Institute.

[50]  S. Gearhart,et al.  Local excision for early rectal cancer: transanal endoscopic microsurgery and beyond. , 2015, Journal of gastrointestinal oncology.

[51]  V. Wong,et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.

[52]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[53]  V. Velculescu,et al.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. , 2014, Cancer discovery.

[54]  Yue-yu Chen,et al.  Transanal endoscopic microsurgery versus laparoscopic lower anterior resection for the treatment of T1-2 rectal cancers. , 2013, Hepato-gastroenterology.

[55]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Kulig,et al.  Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5-year follow-up , 2011, Langenbeck's Archives of Surgery.

[58]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[59]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[60]  D. Sargent,et al.  Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Putter,et al.  The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma , 2007, Annals of surgery.

[63]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[64]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[65]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[66]  J. Tjandra,et al.  Local excision of rectal cancer , 2001, Diseases of the colon and rectum.

[67]  H. Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.

[68]  J. Brierley,et al.  Local excision and postoperative radiotherapy for distal rectal cancer. , 2001, International journal of radiation oncology, biology, physics.

[69]  S. Wexner,et al.  Surgeon influenced variables in resectional rectal cancer surgery , 2000, Diseases of the colon and rectum.

[70]  A. Mellgren,et al.  Is local excision adequate therapy for early rectal cancer? , 2000, Diseases of the colon and rectum.

[71]  J. Guillem,et al.  Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. , 1999, International journal of radiation oncology, biology, physics.

[72]  C. Compton,et al.  Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. , 1999, Annals of surgery.

[73]  P. Dobrin,et al.  Characteristics of rectal carcinomas that predict the presence of lymph node metastases: implications for patient selection for local therapy , 1998, Journal of surgical oncology.

[74]  P. T. Phang,et al.  The use of endoluminal ultrasound for malignant and benign anorectal diseases , 1997 .

[75]  K. Schmid,et al.  Surgical cure for early rectal carcinomas (T1) , 1996, Diseases of the colon and rectum.

[76]  R. Nozaki,et al.  Management of early invasive colorectal cancer , 1995, Diseases of the colon and rectum.

[77]  B. Minsky,et al.  Variables correlated with the risk of lymph node metastasis in early rectal cancer , 1992, Cancer.

[78]  A. Lindblad,et al.  Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[79]  Corey Pelz,et al.  Endoscopic Surgery in the Rectum , 1985, Endoscopy.

[80]  R. Heald,et al.  The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? , 1982, The British journal of surgery.

[81]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[82]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[83]  E. Lezoche,et al.  A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy , 2007, Surgical Endoscopy.